While biotech stocks conjure images of all-or-nothing risky stocks, nothing could be further from the truth. The reality is that many of these companies feature huge pipelines, billion dollar-approved blockbuster drugs and hefty cash flows. Our latest pick in our Best High Dividend Stocks Model Portfolio is a prime example of this in action.
Our pick cut its teeth on a variety of HIV medications, and it features one of the largest portfolios of drugs treating the condition. The firm’s near monopoly on the disease has helped produce ample cash flows and allowed our pick to expand further into oncology and other viral treatments. The end result for investors has been both rising dividends and a high yield.
And with plenty of blockbusters left in its pipeline, as well as cash available for further M&A, our pick is poised to keep growth and dividends coming for the long haul. With more than 5 years’ worth of dividend increases under its belt, our pick makes an ideal high-yielding growth choice. Investors should watch for the stock’s ex-dividend on Tuesday, June 14.
In order to make more room for our biotech pick, we’ve decreased our position in two pipeline stocks and a technology firm.
You can check out the Best High Dividend Stocks Model Portfolio to explore all the stocks.
